Sir, Over recent months there have been many communications exhorting paediatricians and anaesthetists to prescribe analgesics for newborn infants.1 2 Such prescriptions are not without risk with problems mainly manifesting as respiratory or cardiovascular depression. Indeed opiates are frequently used to stop an infant struggling against the ventilator. Little is known, however, about how preterm infants handle opiate analgesics. We therefore undertook a study of alfentanil pharmacokinetics in preterm infants undergoing paralysis and mechanical ventilation for respiratory distress syndrome. Alfentanil was chosen because of its rapid distribution and short half life in adults and older children. We were concerned that other drugs may have such prolonged excretion rates that accumulation might occur with repeated doses. For example, among preterm infants undergoing surgery for patent ductus arteriosus the half life of fentanyl may be prolonged to over 17 hours compared with two hours in adults.3 There are no comparable data for other opiates. Our aim was to establish a regime for continuous infusion or safe regular bolus dosage.
This study was approved by the local ethical committee. The pharmacological data will be reported separately. Recordings were made for 20 children, median gestation 30 weeks (range 25-36), median birth weight 1348 g (range 690-4084) at <24 hours age (n=10), 25-48 hours (n=5), and 49-84 hours (n=5). All children had indwelling arterial catheters and continuous direct blood pressure monitoring.
The intravenous administration over two minutes of 20 ig/kg alfentanil produced a rapid and significant fall in both heart rate and blood pressure ( 
